For the quarter ending 2026-03-31, VRCA made $5,023K in revenue. -$9,682K in net income. Net profit margin of -192.75%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 5,023 | 5,092 | 14,344 | 12,702 |
| Cost of product revenue | 544 | 675 | 754 | 340 |
| Cost of collaboration revenue | - | - | 355 | 154 |
| Cost of license and collaboration revenue | 345 | 911* | - | - |
| Selling, general and administrative | 9,989 | 8,117 | 9,403 | 8,852 |
| Research and development | 3,860 | 2,520 | 2,205 | 1,846 |
| Loss on disposal of equipment | - | -61* | - | - |
| Total operating expenses | 14,738 | 12,284 | 12,717 | 11,192 |
| Loss from operations | -9,715 | -7,192 | 1,627 | 1,510 |
| Interest income | 201 | 205 | 159 | 228 |
| Interest expense | 160 | 1,314 | 2,094 | 2,131 |
| Change in fair value of derivative liability | 0 | 1,762 | 34 | 598 |
| Loss on extinguishment of debt | - | -1,533* | - | - |
| Other expense | -8 | -1* | 0 | -1 |
| Total other income (expense), net | 33 | -882 | -1,901 | -1,306 |
| Net loss | -9,682 | -8,074 | -274 | 204 |
| Basic EPS | -0.45 | -0.758 | -0.03 | 0.02 |
| Diluted EPS | -0.45 | -0.758 | -0.03 | 0.02 |
| Basic Average Shares | 21,305,025 | 10,652,367* | 9,490,083 | 9,488,055 |
| Diluted Average Shares | 21,305,025 | 10,652,367* | 9,490,083 | 9,490,600 |
Verrica Pharmaceuticals Inc. (VRCA)
Verrica Pharmaceuticals Inc. (VRCA)